Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
Articles > Article · 2019
Authors: Heiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, Florin Alexandru Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus Salih AKARCA, SELİM GÜREL, Stefan Zeuzem, Andreas Erhardt, Stefan Lueth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Kristina Weber, Judith Stift, Ulrike Wittkop, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Hans Peter Dienes, Markus Cornberg, Armin Koch, Michael P. Manns
The Lancet Infectious Diseases, Journal Indexed in SCI Expanded, International, WoS, 2019, vol 19, pp 275-286
DOI: 10.1016/s1473-3099(18)30663-7
Summary
Background Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of patients only. Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppression is unknown. We aimed to explore whether prolonged treatment of HDV with 96 weeks of peginterferon would increase HDV RNA response rates and reduces post-treatment relapses.